InflaRx (IFRX) Asset Writedowns and Impairment (2018 - 2019)
InflaRx's (IFRX) quarterly Asset Writedowns and Impairment came in at -$16854.6 in Q2 2019, down 127.16% year-over-year from $62059.1 in Q2 2018, and down 127.16% quarter-over-quarter from $62059.1 in Q2 2018.
Powered by 
Analysis
InflaRx (IFRX) Asset Writedowns and Impairment (2018 - 2019) Analysis & Trends
InflaRx has disclosed Asset Writedowns and Impairment across 2 years of filings, most recently posting -$16854.6 for Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn |